193882-86-9

Upstream product

• 75-30-9 2-iodo-propane 
• 2411-83-8 methyl-2,3-dihydroxybenzoate 
• 1616290-29-9 2,2-dimethyl-8-(propan-2-yloxy)-4H-1,3-benzodioxin-4-one 
• 124-41-4 sodium methylate 
• 277312-95-5 8-hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 
• 303-38-8 2,3-Dihydroxybenzoic acid 

Downstream Products

• 193882-88-1 methyl 5-bromo-2-methoxy-3-(1-methylethoxy)benzoate 
• 193882-85-8 5-bromo-2-methoxy-3-(1-methylethoxy)benzoic acid 
• 1616290-33-5 methyl 2-(2-{[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]amino}ethoxy)-3-(propan-2-yloxy)benzoate 
• 1616290-31-3 methyl 3-(propan-2-yloxy)-2-(prop-2-en-1-yloxy)benzoate 
• 193882-87-0 methyl 5-bromo-3-(1-methylethoxy)salicylate 

Relevant academic research and scientific papers

ARYL AND HETEROARYL FUSED LACTAMS

This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Synthesis and 5-HT-3 receptor binding activity of 5-[125I]iodo-2,3-dimethoxy-N-(1-azabicyclo[2.2.2]oct-3-yl]benzamide and its 5-halogen-2-alkoxyl homologues

(S)-5-Iodo-2,3-dimethoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamide (MIZAC) was prepared from 5-iodo-2,3-dimethoxybenzoyl chloride and (S)-3-aminoquinuclidine. [125I]Iodode-stannylation of its corresponding 5-tri-n-butyltin derivative gave [125I]-MIZAC at 1800 Ci/mmol. Binding of [125I]-MIZAC in rat entorhinal cortex revealed a K(D) of 1.37 ± 0.21 nM. A series of racemic 2-O-alkyl derivatives of MIZAC were prepared and 5-HT-3 receptor affinities were determined by inhibition of [125I]-MIZAC binding. Optimal affinity for the receptor was obtained with small, electron-withdrawing substituents in the aromatic 5-position and with bulky substituents in the 3-position. [125I]-MIZAC is a selective radioligand useful for in vitro identification of the 5-HT-3 receptor.